Designer GLP1 poly-agonist peptides in the management of diabesity

Statham, Laura; Pelling, Melina; Hanson, Petra; Kyrou, Ioannis; Randeva, Harpal S.; Barber, Thomas M.

doi:10.1080/17446651.2023.2204976

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(iii) Currently, MAFLD lacks bespoke therapies that have been designed, assessed, and approved specifically for the purpose of managing this condition. The dawn of the dual and triple incretin agonist therapies (including those that combine GLP1 with glucagon such as cotadutide with associated improvements in hepatic fatty index), will likely feature prominently in future treatment algorithms for MAFLD [ 110 ].…”

Section: Concluding Remarks: How To Optimise Metabolic Liver Healthmentioning

confidence: 99%

“…Accordingly, there is a disconnection between the metabolic health implications of MAFLD and our limited clinical armamentarium with which to accurately diagnose and effectively manage this important condition. The development and implementation of specific pharmacotherapies for MAFLD, including the dual and triple incretin agonists [ 110 ] will help to raise awareness of MAFLD, and hopefully catalyze the development of accurate and reliable non-invasive diagnostic tests. Such novel pharmacotherapies for MAFLD should also provide an impetus for both patients and healthcare professionals to engage in timely screening for MAFLD, enabling prompt initiation of an effective management strategy.…”

Section: Concluding Remarks: How To Optimise Metabolic Liver Healthmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks

et al. 2023

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD) has now surpassed alcohol excess as the most common cause of chronic liver disease globally, affecting one in four people. Given its prevalence, MAFLD is an important cause of cirrhosis, even though only a small proportion of patients with MAFLD ultimately progress to cirrhosis. MAFLD suffers as a clinical entity due to its insidious and often asymptomatic onset, lack of an accurate and reliable non-invasive diagnostic test, and lack of a bespoke therapy that has been designed and approved for use specifically in MAFLD. MAFLD sits at a crossroads between the gut and the periphery. The development of MAFLD (including activation of the inflammatory cascade) is influenced by gut-related factors that include the gut microbiota and intactness of the gut mucosal wall. The gut microbiota may interact directly with the liver parenchyma (through translocation via the portal vein), or indirectly through the release of metabolic metabolites that include secondary bile acids, trimethylamine, and short-chain fatty acids (such as propionate and acetate). In turn, the liver mediates the metabolic status of peripheral tissues (including insulin sensitivity) through a complex interplay of hepatokines, liver-secreted metabolites, and liver-derived micro RNAs. As such, the liver plays a key central role in influencing overall metabolic status. In this concise review, we provide an overview of the complex mechanisms whereby MAFLD influences the development of insulin resistance within the periphery, and gut-related factors impact on the development of MAFLD. We also discuss lifestyle strategies for optimising metabolic liver health.

show abstract

Section: Concluding Remarks: How To Optimise Metabolic Liver Healthmentioning

confidence: 99%

Section: Concluding Remarks: How To Optimise Metabolic Liver Healthmentioning

confidence: 99%

Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks

et al. 2023

View full text Add to dashboard Cite

show abstract

The Impact of Hyperandrogenism in Female Obesity and Cardiometabolic Disease Associated with Polycystic Ovary Syndrome

Barber,

Hanson,

Franks

2024

Obesity

View full text Add to dashboard Cite

GLP-1 and Body Weight: A Scientometric Analysis About How to Select the Best Articles Containing Pharmacological Treatment Methods

Repanovici,

Rogozea,

Pantea

2024

American Journal of Therapeutics

View full text Add to dashboard Cite

Background: Medications initially intended for diabetes treatment are now being used by other patients for weight loss. In the specialized literature, there are numerous meta-analyses investigating this aspect. Areas of Uncertainty: The authors aimed to explore whether the application of scientometric methods for literature review within meta-analyses could provide clear answers to specific research questions. This approach could help develop a rapid system for selecting articles to read during the information process for clinicians or researchers. Data Sources: We obtained research data from Web of Science Core Collection, using the search phrase “GLP-1 AND Body Weight,” reviews from the past 5 years. This approach led to the identification of 31 relevant articles in the field. Results: A total of 31 reviews were identified in the WOS database and investigated using the VOSviewer bibliographic coupling method. Among these, 7 reviews were found to have the highest influence. The authors analyzed these articles and determined that only these 7 reviews directly address the research question. In addition, an analysis of the impact factor of the journals where the articles are published, the influence power of these articles, and the countries of origin of the authors was conducted. A strong correlation was demonstrated between the impact factor and the total link strength for these 7 reviews. The correlation coefficient of 0.116709 between journal impact factor and number of citations suggests a very weak or nonexistent relationship. A strong positive correlation of 0.879736 exists between journal impact factor and total link strength, indicating a significant association. The correlation coefficient of −0.12505 between citations and total link strength shows a very weak or negligible relationship. Conclusions: Scientometric methods such as VOSviewer are useful in the work of both researchers and clinicians, highlighting the fact that articles in a research field can be identified by several criteria: impact factor, number of citations, authors from research teams that addressed this topic. The weak correlation between journal impact factor and number of citations implies that the prestige of the journal does not significantly affect the citation count of articles. Researchers should focus on the quality and relevance of their work rather than solely targeting high-impact journals. However, the strong positive correlation between impact factor and total link strength suggests that articles in prestigious journals are more likely to share content similarities. Researchers should consider this when selecting journals for publication and aim to contribute to impactful and interconnected research areas. This approach allows quick and easy identification of key articles, serving as a fundamental basis for rapid analysis of research in the field, starting from the analysis of authors' competence, degree of trust of the journal, or degree of interest that researchers have for that article.

show abstract

Designer GLP1 poly-agonist peptides in the management of diabesity

Cited by 4 publications

References 83 publications

Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks

Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks

The Impact of Hyperandrogenism in Female Obesity and Cardiometabolic Disease Associated with Polycystic Ovary Syndrome

GLP-1 and Body Weight: A Scientometric Analysis About How to Select the Best Articles Containing Pharmacological Treatment Methods

Contact Info

Product

Resources

About